Drug intelligence / Profile preview

AGN-201904

Development stage: Phase 1
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

AGN-201904 is a slowly-absorbed, acid-stable pro-proton pump inhibitor (pro-PPI) that is rapidly converted to omeprazole in the systemic circulation, giving a prolonged residence time. It was developed as an enteric-coated formulation for the treatment of gastric ulcer disease and prevention of peptic ulcers. In clinical studies, AGN-201904 produced significantly greater and more prolonged acid suppression than esomeprazole, with particularly improved nocturnal acid suppression. The drug was designed to provide true once-a-day treatment with better clinical efficacy compared to current PPIs.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on AGN-201904.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGN-201904.

Explore the full profile